VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 225.2% in August

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 2,224,050 shares, a growth of 225.2% from the August 15th total of 683,892 shares. Based on an average daily volume of 40,219,957 shares, the days-to-cover ratio is currently 0.1 days. Currently, 17.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.00.

Institutional Trading of VolitionRX

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC boosted its position in shares of VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67,848 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in VolitionRX during the fourth quarter valued at $34,000. Jane Street Group LLC purchased a new stake in VolitionRX during the fourth quarter valued at $28,000. Geode Capital Management LLC lifted its position in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 85,816 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRX Price Performance

Shares of VNRX stock traded down $0.03 during mid-day trading on Friday, hitting $0.31. The company had a trading volume of 1,046,498 shares, compared to its average volume of 22,753,156. VolitionRX has a 52-week low of $0.31 and a 52-week high of $14.80. The stock’s 50 day moving average price is $0.75 and its 200-day moving average price is $2.11. The company has a market capitalization of $4.23 million, a P/E ratio of -0.08 and a beta of 1.10.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.41 million. On average, equities research analysts expect that VolitionRX will post -2.36 earnings per share for the current year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.